Tirzepatide, marketed as Mounjaro® by Eli Lilly, is the first dual GIP/GLP-1 receptor agonist approved for Type 2 Diabetes (T2D) treatment. Approved by the FDA in May 2022, it improves glycemic control and induces significant weight loss. Clinical trials, including SURPASS-4, showed superior HbA1c and weight reductions compared to other therapies. Tirzepatide also demonstrated lower mortality than insulin glargine during the COVID-19 pandemic, suggesting broader health benefits and potential future applications beyond diabetes.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about TIRZEPATIDE by Hubio Pharm, consult with your doctor or healthcare professional.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Home
